A
August Bioservices
A contract development and manufacturing organization, providing drug discovery, development, and pharmaceutical manufacturing services
About August Bioservices
August Bioservices is a US-based Contract Development and Manufacturing Organization (CDMO), offering comprehensive drug development services. The company operates in the pharmaceutical industry, serving clients of all sizes and stages, from pre-clinical to commercial. Their services range from end-to-end drug research and development to laboratory services and sterile fill/finish manufacturing.
August Bioservices' business model is unique in that it combines the expertise and capabilities of a large CDMO with a customer-focused approach. This hybrid model allows them to cater to a wide range of clients, from small startups to large pharmaceutical companies. They offer full drug development programs, which means they can handle all aspects of drug development, from initial research to testing and manufacturing.
The company generates revenue by charging clients for these services. Their integrated approach to drug development, testing, and manufacturing allows them to provide a seamless service, which can save clients time and money.
In addition, August Bioservices prides itself on its quality-driven approach. They adhere to current Good Manufacturing Practices (cGMP), which are regulations enforced by the FDA to ensure the quality of pharmaceutical products. This commitment to quality, combined with their comprehensive services and customer-focused approach, makes August Bioservices a strong player in the pharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Nashville, United States
- Employees
- 178
- Open positions
- 14
- Dealroom signal
- 86.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2022 | $65M | $260M | Polaris Partners · Oak HC/FT | ↗ |
| SERIES AOther financing | May 2021 | $24M | $94M | Polaris Partners · Oak HC/FT | — |
Growth signals
Latest recorded traffic for August Bioservices is 2.7K monthly website visits, down 10% over the last three months. August Bioservices's team grew 4.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Oak HC/FT
Polaris Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about August Bioservices on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See August Bioservices’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.